A Multi center, randomized, open label clinical trial of efficacy of HFRT regimen as an add-on therapy to conventional treatment versus conventional treatment alone for chronic heart failure

Dr Rohit Sane as a Director0 个研究点目标入组 70 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•To be eligible for the study, patients must meet the following criteria:
•1. Provide written informed consent.
•2. Male or female patients between 25 to 65 years of age with clinical diagnosis of Chronic Heart Failure (CHF).
•3. History of CHF irrespective of angioplasty and coronary artery bypass graft (CABG) on standard Treatment.
•4. Stress test MET value between 3 to 7.
•5. Ejection fraction between 30%-65%
•6. 2D Echo done within 6months

•1.Female patients who are pregnant or lactating or planning to become pregnant during the study period.
•2. Acute Heart Failure.
•3. Patients who had acute decompensated heart failure attack in last 3 months.
•4. Patients who are not on stable dose of standard treatment of chronic heart failure since last 3 months and need upward dose titration will be excluded.
•5.Irritable bowel syndrome.
•6.Clinically diagnosed bleeding piles or prolapsed or fistula (grade I or II piles).
•7.Hemorrhoids (2nd or 3rd degree).
•8.Known case of Asthma or COPD.
•9.Known case of cancer.
•10.Physical disability in any form leading to immobilization.
•11.Uncontrolled hypertension (SBP more than 150 mm of Hg and DBP more than 90 mm of Hg).
•12.Anemia (Hemoglobin less than 10 gm/dL).
•13.Uncontrolled Blood sugar level (fasting below 60 mg/dL and PLBS above 250 mg/dL).
•14 Abnormal thyroid function test.
•15 Patients with hepatic or renal insufficiency.
•16 Participation in another study within 30 days.
•17 Suspected inability or unwillingness to comply with the study procedures.
•18.Suspected hypersensitivity to study medication.

发起方

Dr Rohit Sane as a Director